



an Open Access Journal by MDPI

New Generation Imaging in Oncology 2.0

Guest Editors:

Dr. Francesco Ceci

Nuclear Medicine Division,
European Institute of Oncology
(IEO) IRCCS, Milan, Italy

Dr. Marcus Unterrainer

Department of Radiology,
Klinikum der Universität
München, Munich, Germany

Dr. Michel Eisenblätter

King's College, University of
Freiburg, London, UK

Deadline for manuscript
submissions:

closed (31 July 2022)

Message from the Guest Editors

The introduction of positron emission tomography (PET) imaging, in oncology has already changed the clinical outcomes and therapeutic management of oncological patients. Several PET radiopharmaceuticals have been proposed in oncology over the last decade, and these diagnostic techniques are now currently placed under the umbrella term “new-generation imaging”.

The most successful approaches proposed for PET imaging, other than FDG-PET, have been receptorial tracers targeting the somatostatin receptors (SSRs) and the prostate-specific membrane antigen (PSMA), proposed to investigate neuroendocrine tumors and prostate cancer, respectively. However, FDG-PET still holds an innovative position when considering its application to evaluate the efficacy of new-generation therapeutic approaches in oncology, like immunotherapy. Finally, the application of radiomics in PET imaging is an emerging field.

This Special Issue aims to collect innovative studies regarding the translational imaging of new-generation PET imaging in oncology. Pre-clinical studies and comprehensive reviews regarding these innovative diagnostic and therapeutic approaches will be considered.



mdpi.com/si/84673



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI